Kintegral Advisory’s West Pharmaceutical WST Stock Holding History

Kintegral Advisory’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37M	Hold	3,813	–	–	0.11%	157
2026 Q1	$956K	Sell	3,813 -169	-4%	-$42K	0.09%	172
2025 Q4	$1.1M	Sell	3,982 -109	-3%	-$29.8K	0.09%	165
2025 Q3	$1.07M	Sell	4,091 -18	-0.4%	-$4.38K	0.09%	173
2025 Q2	$899K	Sell	4,109 -6	-0.1%	-$1.28K	0.08%	183
2025 Q1	$921K	Sell	4,115 -13	-0.3%	-$3.58K	0.09%	183
2024 Q4	$1.35M	Sell	4,128 -192	-4%	-$60.4K	0.13%	155
2024 Q3	$1.3M	Sell	4,320 -57	-1%	-$17.5K	0.12%	161
2024 Q2	$1.44M	Sell	4,377 -6,736	-61%	-$2.38M	0.14%	149
2024 Q1	$4.4M	Sell	11,113 -35	-0.3%	-$12.9K	0.44%	62
2023 Q4	$3.93M	Sell	11,148 -71	-0.6%	-$25.1K	0.43%	61
2023 Q3	$4.21M	Sell	11,219 -7	-0.1%	-$2.71K	0.52%	55
2023 Q2	$4.29M	Hold	11,226	–	–	0.51%	55
2023 Q1	$3.89M	Sell	11,226 -603	-5%	-$176K	0.5%	59
2022 Q4	$2.78M	Buy	+11,829	New	+$2.8M	0.37%	91

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Kintegral Advisory's WST Position: Q2 2026 in Review

Kintegral Advisory held its West Pharmaceutical (WST) position steady in Q2 2026 at 3,813 shares worth $1.37M. The position accounts for 0.11% of the portfolio, ranked #157.

Kintegral Advisory first reported a position in WST in Q4 2022 and has held it in 15 quarters since. The position peaked at $4.4M in Q1 2024. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

Kintegral Advisory held 3,813 shares of West Pharmaceutical worth $1.37M as of Q2 2026.
Kintegral Advisory left its West Pharmaceutical share count unchanged in Q2 2026.
West Pharmaceutical made up 0.11% of Kintegral Advisory's portfolio in Q2 2026, its #157 holding.
Kintegral Advisory first reported a position in West Pharmaceutical in Q4 2022 and has held it in 15 quarters since.
Kintegral Advisory's West Pharmaceutical position peaked at $4.4M in Q1 2024.
831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Kintegral Advisory's 13F filing for Q2 2026, filed 29 Jul 2026.